KRYS — Krystal Biotech Share News
0.000.00%
Last trade - 00:00- $9.77bn
- $8.92bn
- $389.13m
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion
Brief: UK's MHRA Approves Beremagene Geperpavec For Treatment Of Dystrophic Epidermolysis Bullosa
Krystal Biotech Q1 revenue rises 32% on VYJUVEK growth
U.S. RESEARCH ROUNDUP-Carpenter Technology, IBM, Ulta Beauty
Krystal Biotech Q4 revenue rises 17.5% driven by VYJUVEK
Brief: Krystal Biotech Announces Rmat Designation Granted By FDA
Brief: Rpt-Krystal Biotech Expects VYJUVEK Net Revenue Of $106 Million To $107 Million For Q4 2025
Brief: Krystal Biotech Expects Net Revenue Of $106 Million To $107 Million For Q4 2025
U.S. RESEARCH ROUNDUP-Ardelyx, RPM International, Trubridge
Brief: Krystal Biotech Announces Positive Interim Clinical Update From KB407 Phase 1 CORAL-1 Study
Brief: Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Krystal Biotech Q3 net income triples
Brief: Krystal Biotech Q3 Net Income USD 79.365 Million
Brief: Krystal Biotech Announces FDA Approval Of Updated VYJUVEK Label
Brief: Krystal Biotech Granted FDA Meeting For KB707 For October
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary